M. Verdoia
University of Naples Federico II
19 Papers
134 Citations
M. Verdoia is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Clopidogrel & Ticagrelor. The author has an hindex of 11, co-authored 19 publications.
Chat about Author
Papers
Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study
G. De Luca,Gioel Gabrio Secco,Matteo Santagostino,Luca Venegoni,Sergio Iorio,Ettore Cassetti,M. Verdoia,Lorenzo Coppo,C. Di Mario,Giorgio Bellomo,Paolo Marino +10 more
TL;DR: Uric acid is not associated with platelet aggregation, the extent of coronary artery disease and IMT, and waiting for the results of additional large studies, uric acid may not be considered as a risk factor for coronary arteries disease and atherosclerosis.
117
Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
M. Verdoia,Alon Schaffer,Lucia Barbieri,Ettore Cassetti,Raffaele Piccolo,Gennaro Galasso,Paolo Marino,Fabiola Sinigaglia,Giuseppe De Luca +8 more
TL;DR: Present meta-analysis shows that the new ADP antagonists prasugrel, ticagrelor, and cangrelor are associated to significant reduction of mortality, reinfarction, RI, and ST respect to clopidogrel alone, without significant increase in bleeding complications.
76
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
M. Verdoia,Patrizia Pergolini,Roberta Rolla,Matteo Nardin,A. Schaffer,Lucia Barbieri,Paolo Marino,Giorgio Bellomo,H. Suryapranata,G. De Luca +9 more
TL;DR: In patients receiving dual antiplatelet therapy, advanced age is independently associated with a reduced effectiveness of ADP antagonists and a higher rate of HRPR with both clopidogrel and ticagrelor.
64
Meta-analysis of 14 trials comparing bypass grafting vs drug-eluting stents in diabetic patients with multivessel coronary artery disease.
TL;DR: It is demonstrated that among diabetic patients with multivessel disease and/or left main disease, CABG provides benefits in mortality and TVR, especially in high-risk patients but it is counterbalanced by a higher risk of stroke.
37
Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials
TL;DR: Niacin and CETP inhibitors do not influence cardiovascular mortality, and significant benefits in MI and coronary revascularization were observed with niacin, despite the higher occurrence of diabetes.
31